Free Trial

Lai Wang Sells 1,028 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines logo with Medical background

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,028 shares of BeOne Medicines stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $260.00, for a total value of $267,280.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Lai Wang also recently made the following trade(s):

  • On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total value of $118,143.90.
  • On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total value of $313,552.80.
  • On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total value of $353,850.78.

BeOne Medicines Stock Down 5.2%

Shares of NASDAQ ONC traded down $13.29 during midday trading on Friday, hitting $241.20. 400,801 shares of the company's stock were exchanged, compared to its average volume of 340,778. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $141.84 and a 12 month high of $287.88. The business has a 50 day moving average of $247.90. The company has a market capitalization of $26.44 billion, a price-to-earnings ratio of -64.84 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. On average, equities research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ONC. Sanford C. Bernstein set a $259.00 target price on BeOne Medicines in a research report on Thursday, March 13th. Morgan Stanley raised their price target on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday. Royal Bank Of Canada upgraded BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 target price for the company in a research note on Friday. Bank of America upgraded BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, JMP Securities set a $348.00 target price on BeOne Medicines in a research note on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $320.67.

Get Our Latest Research Report on ONC

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

Featured Stories

Insider Buying and Selling by Quarter for BeOne Medicines (NASDAQ:ONC)

Should You Invest $1,000 in BeOne Medicines Right Now?

Before you consider BeOne Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.

While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Strategy Beat the S&P—And Most Investors Ignore It
Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines